Indication | 2008 | 2012 | ||||
| n | % | n | % | ||
Across indication |
|
|
|
| ||
all | 3149 | 100.0 | 2734 | 100.0 | ||
Patients with SRWA | 1718 | 54.6 | 1429 | 52.3 | ||
| and WMR | 253 | 8.0 | 1095 | 40.1 | |
| no WMR | 1465 | 46.5 | 334 | 12.2 | |
Patients without SRWA | 1431 | 45.4 | 1305 | 47.7 | ||
| and WMR | 135 | 4.3 | 712 | 26.0 | |
Patients with WMR | 388 | 12.3 | 1807 | 66.1 | ||
Patients with CM | 0 | 0.0 | 553 | 20.2 | ||
Musculoskeletal Disorders |
|
|
|
| ||
all | 1521 | 100 | 1575 | 100 | ||
Patients with SRWA | 833 | 54.8 | 888 | 56.4 | ||
| and WMR | 253 | 16.6 | 726 | 46.1 | |
| no WMR | 580 | 38.1 | 162 | 10.3 | |
Patients without SRWA | 688 | 45,2 | 45.2 | 43.6 | ||
| and WMR | 135 | 8.9 | 285 | 18.1 | |
Patients with WMR | 388 | 25.5 | 1011 | 64.2 | ||
Patients with CM | 0 | 0.0 | 343 | 21.8 | ||
Cardiovascular Diseases |
|
|
|
| ||
all | 467 | 100.0 | 199 | 100.0 | ||
Patients with SRWA | 229 | 49.0 | 70 | 35.2 | ||
| and WMR | 0 | 0.0 | 36 | 18.1 | |
| no WMR | 229 | 49.0 | 30 | 15.1 | |
Patients without SRWA | 238 | 51.0 | 129 | 64,8 | ||
| and WMR | 0 | 0.0 | 34 | 17.1 | |
Patients with WMR | 0 | 0.0 | 66 | 33.2 | ||
Patients with CM | 0 | 0.0 | 17 | 8.5 | ||
Cancer |
|
|
|
| ||
all | 398 | 100.0 | 255 | 100.0 | ||
Patients with SRWA | 283 | 71.1 | 174 | 68.2 | ||
| and WMR | 0 | 0.0 | 38 | 14.9 | |
| no WMR | 283 | 71.1 | 136 | 53.3 | |
Patients without SRWA | 115 | 28.9 | 81 | 31.8 | ||
| and WMR | 0 | 0.0 | 5 | 2.0 | |
Patients with WMR | 0 | 0.0 | 43 | 16.9 | ||
Patients with CM | 0 | 0.0 | 12 | 4.7 | ||
Psychosomatic Disorders |
|
|
|
| ||
all | 763 | 100.0 | 705 | 100.0 | ||
Patients with SRWA | 373 | 48.9 | 297 | 42.1 | ||
| and WMR | 0 | 0.0 | 295 | 41.8 | |
| no WMR | 373 | 48.9 | 2 | 0.3 | |
Patients without SRWA | 390 | 51.1 | 408 | 57.9 | ||
| and WMR | 0 | 0.0 | 392 | 55.6 | |
Patients with WMR | 0 | 0.0 | 687 | 97.4 | ||
Patients with CM | 0 | 0.0 | 181 | 25.7 | ||